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Familial hypercholesterolemia is an autosomal dominant disorder caused by a mutation of the gene 
for the low-density lipoprotein receptor and is characterized by rapidly progressing coronary 
atherosclerosis. We assessed the long-term results of coronary artery bypass grafting performed 
during the past 13 years in 62 patients with heterozygous familial hypercholesterolemia, whose mean 
plasma total and low-density lipoprotein cholesterol level was 327 mg/dl and 238 mg/dl, respectively. 
The patients had severe coronary atherosclerosis, with coronary stenosis index of 19.7, and the 
prevalence of extracoronary atherosclerotic lesions was 27%. Sixty-one patients underwent success- 
ful coronary artery bypass operation, with an average of 2.5 grafts, and the coronary stenosis index 
decreased to7.1. After operation, all patients consumed a cholesterol-lowering diet and received rug 
therapy with pravastatin, probucol, or cholestyramine. Seven patients who were resistant o drug 
therapy were treated with plasma low-density lipoprotein apheresis. The cholesterol-lowering 
therapy reduced plasma total cholesterol level by 37%, low-density lipoprotein cholesterol level by 
42%, and low-density lipoprotein/high-density l poprotein cholesterol ratio by 37% (p < 0.001). 
During the follow-up eriod (mean, 52 months; range, 10 to 157 months), there was no cardiac death, 
but three patients died of malignant disease. The actuarial survival rate was 95% at 5 years and 89% 
at 12 years after operation. The actuarial freedom from recurrent angina was 90% at 5 years and 53% 
at 11 years after operation. Four patients underwent reoperation, an average of 8 years postopera- 
tively, because of vein graft atherosclerosis. In spite of severe coronary atherosclerosis, these patients 
with familial hypercholesterolemia showed good long-term outcome after coronary artery bypass 
operation. The present findings suggest that aggressive use of arterial grafts, intensive cholesterol- 
lowering drug therapy, and low-density lipoprotein apheresis may be useful in patients with familial 
hypercholesterolemia. (J THORAC CARDIOVASC SURG 1995;109:364-9) 
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Hyper l ip idemia  is one of the major risk factors 
for coronary atherosclerosis. Familial hypercholes- 
terolemia (FH) is an autosomal dominant disorder 
caused by a mutation of the gene for the low-density 
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lipoprotein (LDL) receptorJ FH, which is charac- 
terized by high plasma level of cholesterol and the 
development of cutaneous and tendon xanthoma, is
frequently associated with premature coronary heart 
disease. 1-3 Homozygous FH occurs in approximately 
one out of every 1 million persons and usually causes 
death before the patient reaches the age of 30.1'4 
Heterozygous FH is a more common disorder, 
occurring in approximately one out of every 500 
persons in Japan and in Western countries. 1'3'5 
Coronary stenosis usually develops in patients with 
heterozygous FH in the second decade of life and 
progresses more rapidly than that in the general 
population. 6 About 70% of patients with heterozy- 
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Fig. 1. Coronary artery segments and coronary stenosis index. 
gnus FH in Japan 3 and in European countries 2'7 die 
of coronary heart disease. 
Coronary artery bypass grafting operation (CABG) 
has been performed in patients with FH to relieve 
myocardial ischemia and to diminish morbidity and 
mortality of myocardial infarction, 8'9 and there is 
concern regarding the long-term prognosis after 
CABG. Because of the rapid progression of coronary 
atherosclerosis in patients with FH, a surgical strategy 
and intensive cholesterol-lowering therapy are neces- 
sary. This article includes our 13-year experience with 
CABG in 62 consecutive patients with heterozygous 
FH and their long-term outcome. The findings in 
extreme cases have important implications for the 
surgical and medical treatment of patients with coro- 
nary atherosclerosis. 
Patients and methods 
Sixty-two patients with FH underwent CABG between 
June 1980 and May 1993 at Kanazawa University Medical 
Center. The patient group included 46 men and 16 women 
who ranged in age from 35 to 74 years, with a mean age of 
54 years (52 years for men and 61 years for women). FH 
was diagnosed according to the following two criteria: 
primary hypercholesterolemia (above 230 mg/dl, regard- 
less of age group) with tendon xanthoma nd primary 
hypercholesterolemia with or without endon xanthoma in
a first-degree relative of patients with FH. All of the 
patients had heterozygous FH. Data for these patients 
were obtained before the introduction of cholesterol- 
lowering drug therapy. The mean level of plasma total 
cholesterol was 327 mg/dl, LDL cholesterol was 238 mg/dl, 
high-density lipoprotein (HDL) cholesterol was 36 mg/dl, 
and triglyceride was 166 mg/dl. Twenty-one (34%) of the 
patients had hypertension, and 22 (35%) had diabetes 
mellitus. Twenty-eight (45%) of the patients had a history 
of remote myocardial infarction. One patient had one- 
vessel coronary artery disease, 14 had two-vessel disease, 
30 had three-vessel disease, and 17 had disease of the left 
main coronary artery. The extent and severity of the 
coronary stenotic changes were assessed by assigning 
scores to each of the 15 coronary artery segments, accord- 
ing to the classification of the American Heart Associa- 
tion Grading Committee. 1°A normal coronary angiogram 
was graded 0, stenosis of less than 25% was graded 1, 25% 
to 49% stenosis was graded 2, 50% to 74% stenosis was 
graded 3, and 75% or more stenosis was graded 4 (Fig. 1). 
The coronary stenosis index was defined as the sum of 
these scores. 11 The mean value of the coronary stenosis 
index before CABG was 19.7 (8 to 36). Thirteen (21%) of 
the patients showed coronary ectasia. The mean left 
ventricular ejection fraction was 0.61 (0.21 to 0.82). Four 
(6%) of the patients had supravalvular ortic stenosis, 
four (6%) had a history of cerebral infarction, four (6%) 
had an abdominal aortic aneurysm, and nine (15%) had 
symptomatic peripheral arterial disease. CABG was per- 
formed with myocardial preservation with the administra- 
tion of cold crystalloid potassium cardioplegic solution. 
Three patients underwent CABG and simultaneous or 
two-staged graft replacement of the abdominal aortic 
aneurysm. Coronary angiography was performed i month 
after CABG in 59 patients, and the coronary stenosis 
index was determined. The severity of coronary stenosis 
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Table I. Changes in plasma lipids and coronary 
stenosis index 
Before After 
Fac!ors ........ treatment treatment., Change .p Value 
Total cholesterol 327 ± 62 205 ± 48 -37% <0.001 
(mg/dl) 
LDL cholesterol 238 -+ 71 138 ± 44 -42% <0.001 
(mg/dl) 
HDL cholesterol 36 -+ 14 32 ± 12 -11% NS 
(mg/dl) 
Triglyceride i66 ± 86 119 ± 72 -29% <0.01 
(mg/dl) 
Total/HDL 10,5 + 4,4 7.7 -+ 3.2 -27% <0.001 
cholesterol 
LDL/HDL 7,5 ± 3,8 4,7 ± 2.2 -37% <0.001 
cholesterol 
Coronary 19.7 ± 6,2 7.1 -+ 4.3 -64% <0.001 
stenosis ndex 
Values are mean _+ standard deviation. 
was graded 0 when postoperative angiography indicated 
complete revascularizauon f the target coronary artery. 
After the operation~ all of the patients received diet 
therapy a'rM Cholesterol-lowering drug therapy to reduce 
cholesterol level to less than 180 mg/dl and LDL choles- 
terol level to less than i30 mg/dl. Cholesterol-lowering 
drugs included pravastatin, probucol, or cholestyramine. 
Seven (11%) patients who were resistant to drug therapy 
received treatment with LDL apheresis. 12 Patients with 
hypertension or diabetes received antihypertensive or 
antidiabetic diet and drug therapy as well. The average 
duration of follow-up after the initial operation was 52 
months (range, 10 to 157 months). Actuarial freedom 
from recurrent angina and actuarial survival after CABG 
were calculated by the Kaplan-Meier method. Cumulative 
data are expressed as mean-  standard eviation. Con- 
tinuous variable~ were analyzed by Student's t test to 
detect significant (p < 0.05) differences between the 
measured variables. 
Results 
Sixty-one (98%) of the patients underwent suc- 
cessful CABG, and the average number of grafts per 
patient was 2.5. Twenty-seven patients received sa- 
phenous vein grafts only, but, beginning in 1986, 39 
patients received arterial grafts, including 44 inter- 
nal thoracic arteries and 11 right gastroepiploic 
arteries. Eight (13%) of the patients had severe 
atherosclerosis of the ascending aorta. Perioperative 
myocardial infarction developed in two patients but 
was successfully treated with intraaortic balloon 
pumping. One patient died of graft-versus-host dis- 
ease resulting from a blood transfusion. All but two 
patients became free of angina after the operation. 
The overall graft patency rate in the 59 patients after 
CABG was 94%; this rate was 100% for all 44 
internal thoracic arteries and 10 of the gastroepip- 
Table II. Changes in plasma lipids and coronary 
stenosis index in seven patients with FH who 
underwent CABG and LDL apheresis 
Before After 
Factors treatment treatment Change p Value 
Total cholesterol 392 + 58 158 -+ 26 -60% <0.001 
(mg/dl) 
LDL cholesterol 326 -+ 58 107 --- 22 -67% <0.001 
(mg/dl) 
HDL cholesterol 38 ± 10 36 -+ 6 -5% NS 
(mg/dl) 
Triglyceride 160 +- 96 75 - 49 -53% <0.05 
(mg/dl) 
Total/HDL 10.7 + 2.1 4.5 ± 1.1 -58% <0.001 
cholesterol 
LDL/HDL 8.9 --- 1.9 3.1 ± 0.9 -65% <0.001 
cholesterol 
Coronary 22.9 ± 5.2 7.6 ± 4.6 -67% <0.001 
stenosis ndex 
Values are mean --- standard deviation. 
loic arteries and 91% for 98 saphenous vein grafts. 
The coronary stenosis index was reduced from 19.7 
to 7.1 after operation (p < 0.001). After intensive 
cholesterol-lowering therapy, plasma total choles- 
terol, LDL cholesterol and triglyceride levels, and 
LDL/HDL cholesterol ratio decreased significantly, 
whereas HDL cholesterol level did not change (Ta- 
ble I). The decreases in plasma total and LDL 
cholesterol levels and LDL/HDL cholesterol ratio 
were more marked in the seven patients who under- 
went LDL apheresis (Table II). 
During the follow-up period, angina recurred in 
nine patients (15%). The cause of recurrence was 
vein graft atherosclerosis in five patients and pro- 
gression of native coronary stenosis in four patients. 
One patient had non-fatal myocardial infarction. 
The actuarial freedom from recurrent angina was 
89% at 5 years after operation and 53% at 11 years 
(Fig. 2). No difference was found in actuarial free- 
dom from recurrent angina 5 years after the opera- 
tion between patients who received saphenous vein 
grafts only and patients who received arterial grafts. 
Thirteen patients underwent repeat coronary an- 
giography an average of 5 years after the operation. 
The overall late graft patency rate was 75%; it was 
100% for nine arterial grafts and 65% for 23 saphe- 
nous vein grafts. Three patients underwent percuta- 
neous transluminal coronary angioplasty an average 
of 15 months after the operation. Four patients who 
received saphenous vein grafts only underwent re- 
operation because of vein graft atherosclerosis at an 
average of 8 years (range, 5 to 10 years) after the 
first operation. In these four patients, the coronary 
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Fig. 2. Actuarial freedom from recurrent angina after CABG in the patients with FH. PTCA, Percutane- 
ous transluminal coronary angioplasty; Re CABG, repeat coronary artery bypass grafting. Short vertical lines 
along the course of the solid lines indicate individual patients who were followed up after CABG. The 
symbols for PTCA and Re CABG are positioned at the time of the re-intervention. 
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Fig. 3. Actuarial survival of the patients with FH who underwent CABG. Short vertical ines along the 
course of the solid lines indicate individual patients who were followed up after CABG. 
stenosis index increased from 8.5 after the first 
operation to 17.3 before the second operation. None 
of the patients who received internal thoracic artery 
graft underwent reoperation. None of the seven 
patients who underwent LDL apheresis had recur- 
rent angina for as long as 7 years. There was no 
cardiac death during the follow-up period, but three 
patients died of pancreatic ancer, leukemia, and 
lung cancer, 3, 4 and 7 years after CABG. The 
actuarial survival rate was 95% at 5 years after the 
initial operation and 89% at 12 years (Fig. 3). 
Discussion 
A substantial body of evidence exists that sup- 
ports the concept hat high LDL cholesterol level is 
an independent risk factor for coronary atheroscle- 
rosis. 13-16 Nonlipid coronary risk factors, such as 
hypertension, diabetes, cigarette smoking, and obe- 
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sity, appear to be overridden by the more marked 
risk factor of hereditary hypercholesterolaemia. 6' 7 
Patients with FH constitute a homogeneous group 
of patients with regard to the relationship between 
hypercholesterolaemia andcoronary atherosclerosis 
and are therefore a good model for evaluating the 
long-term outcome after CABG. 
Mabuchi and associates 6 estimated that coronary 
stenosis in male and female patients with heterozy- 
gous FH begins at 17 and 25 years of age, respec- 
tively, and that the coronary stenosis index reaches 
20 at 56 and 69 years of age, respectively. They 
showed that the age at which the coronary stenosis 
index reaches 20 coincides with that at death. The 
patients with FH in the present study had severe 
coronary atherosclerosis, as shown by the mean 
coronary stenosis index of 19.7. The proximity of 
this value to 20 suggests that the patients were at 
risk of death. Comparative angiographic studies 
have shown that the coronary atherosclerosis n
patients with FH is more extensive and severe than 
that in non-FH patients without FH.  9'11 Distal 
coronary artery segments often show diffuse athero- 
sclerotic hange, and complete myocardial revascu- 
larization is difficult in some FH patients. Because 
of its high incidence, coronary ectasia has been 
reported as a characteristic coronary angiographic 
finding in FH patients. 11 
Various extracoronary atherosclerotic lesions are 
present in patients with FH. Although severe athe- 
roma of the aortic valve and root is considered to be 
a characteristic feature of homozygous FH, s Ribeiro 
and associates 17found that some patients with het- 
erozygous FH had severe supravalvular aortic 
changes imilar those with homozygous FH.  17 Four 
of the patients in the present study had supravalvu- 
lar aortic stenosis, but these lesions were not hemo- 
dynamically significant. Four patients who under- 
went reoperation showed severe atherosclerosis of
the ascending aorta, which required special atten- 
tion to proximal anastomosis of bypass grafts. Kita 
and associates 18reported that the prevalence of 
abdominal aortic aneurysm in patients with FH was 
26%. It is therefore important to evaluate the 
abdominal aorta and its branches in patients with 
FH in whom the right gastroepiploic artery is con- 
sidered for use as a bypass graft. Nine patients had 
symptomatic atherosclerotic disease of the lower 
extremities. A study with Doppler echocardiography 
showed that peripheral arterial diseases were more 
frequent among patients with FH than in a control 
groupJ 9 Curiously, cerebral infarction is not a char- 
acteristic feature of patients with FH.  2° 
The internal thoracic and right gastroepiploic 
arteries have been used as bypass conduits, with the 
expectation of superior long-term patency. TM 22 In 
spite of the high prevalence of extracoronary ath- 
erosclerotic lesions in patients with FH, the internal 
thoracic and right gastroepiploic arteries show no 
histologic differences from those in patients without 
FH. 23 This findings suggest hat a good long-term 
patency rate can be obtained with arterial grafts in 
patients with FH. We have used arterial grafts in 
97% of our patients with FH during the most recent 
4-year period. The cause of reoperation was vein 
graft atherosclerosis; thus, we believe that arterial 
grafts should be used intensively to promote graft 
patency and to reduce the prevalence of reopera- 
tion. 
Plasma cholesterol level affects atherosclerosis 
progression both in native coronary arteries and in 
bypass grafts. The Cholesterol-Lowering Athero- 
sclerosis Study showed that active lowering of LDL 
cholesterol level with combined colestipol-niacin 
therapy decreased atherosclerosis progression and 
increased regression in native coronary arteries and 
also reduced new lesions in bypass grafts) 4' 15 Inten- 
sive lipid-lowering drug therapy reduced the fre- 
quency of progression of coronary lesions, increased 
the frequency of regression in men with coronary 
artery disease, and elevated apolipoprotein B (or 
LDL cho]esterol) level in patients with a family 
history of coronary artery disease. 24 The coronary 
atherosclerosis in patients with FH progresses more 
rapidly than that in the general populationJ' 2,6, 7 In 
patients with FH who are relatively oung, choles- 
terol-lowering therapy is important o retard coro- 
nary atherosclerosis for a prolonged period after 
CABG. Cholesterol-lowering diet and drug therapy 
are mandatory and, when these are ineffective, 
plasma LDL apheresis is indicated. In the present 
study, intensive cholesterol-lowering therapy includ- 
ing drug therapy and LDL apheresis reduced plasma 
total cholesterol level by 37%, LDL cholesterol level 
by 42%, and LDL/HDL cholesterol ratio by 37%; 
and this therapy reduced cholesterol levels for a 
long time. The actuarial survival rate of the patients 
with FH who underwent CABG in this study was as 
high as the survival probability after CABG in a 
heterogeneous groups of patientsY '26 Although 
angiographic assessment was not conducted in this 
study, the good long-term results uggest that inten- 
sive cholesterol-lowering therapy effectively retards 
atherosclerosis progression i  patients with FH.  27 
The present study showed that, although the 
patients with FH had severe coronary and extra- 
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coronary atherosclerotic lesions, they underwent 
CABG with a low mortality rate. The present find- 
ings suggest frequent use of arterial grafts and 
intensive cholesterol-lowering therapies including 
combined rug therapy and LDL apheresis, and the 
good long-term results suggest hat CABG should 
be performed in patients with FH. However, further 
long-term follow-up is necessary. 
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